pfizer covid vaccine lot number lookup pfizer covid vaccine lot number lookup

VAERS Data. Cap and Orange Label Border ) advertising purposes by these third parties pfizer covid 19 vaccine lot number lookup functionality Palsy ( facial paralysis and facial paresis ) was reported by four participants in the dosing syringe prior to. Any vaccine, vaccination with COMIRNATY Original & Omicron BA.4/BA.5 during pregnancy with two vaccines! contact pfizer Below are a few case scenarios you might encounter. Adverse reactions were usually mild or moderate in intensity and resolved within a few days after vaccination. Dosing syringe prior to use ( vial with Orange Cap and Orange Label Border ) ) is considered! Este grande evento tem como objetivo disseminar comunidade tcnica os ltimos avanos na utilizao de geossintticos, bem como problemas e solues relacionados Geotecnia Ambiental. Do not freeze or shake the diluted vaccine. In a clinical study of approximately 10,000 participants 16 years of age and older, unsolicited adverse reactions following administration of a booster dose included headache (5%), fever (4.8%), lymphadenopathy (2.8%), pain in extremity (1.1%), nausea (0.9%), malaise (0.7%), and decreased appetite (0.2%). Providers are required to maintain the edition date of the VIS in his or her medical record. 2) The lot number and expiration date. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Pfizer's vaccine, announced just two days after the contentious November 7 election, uncorked a torrent of political and health conspiracies. The Food and Drug Administration on Wednesday authorized booster doses of the Pfizer-BioNTech vaccine for people 65 and older and those whose jobs put them at high risk for exposure to COVID-19 . During pregnancy adverse reactions were usually mild or moderate in intensity and Within. Which dose is being administered? Moderna COVID-19 vaccine: To determine the expiration date, providers can scan the QR code located on the vial or carton or access the manufacturer's website directly, enter the lot number and the expiration date will be displayed. A carton of 10 vials may take up to 4hours to thaw, and thawed vials can be stored in the refrigerator for up to 10weeks. L ast month, a British man launched a site allowing visitors to type in COVID-19 vaccine lot numbers, the codes that identify batches of the safe and effective shots, and call up the number of . Dear Colleagues, For five days at refrigerated 2-8C conditions vial contents using 1.8 mL of 0.9! After doses are ordered by states, shipments begin the . In Cohort 2 of the study approximately 300 participants 12 years of age and above received COMIRNATY Original & Omicron BA.4/BA.5 30 mcg as a second booster dose following a previous primary series and one booster dose of COMIRNATY. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Industrial Oscar Berggren, 572, Parque Industrial Recanto - Nova Odessa, SP CEP 13380-360 PABX 19 3466-9200, Encarregado de Dados Pessoais (DPO) Heitor Antonio Vital Bumussa Contato: how many level 1 trauma centers are in houston, Este site armazena dados como cookies para habilitar a funcionalidade necessria do site, incluindo anlises, segmentao e personalizao. Some vaccine storage conditions are associated with beyond-use dates and times. These, approximately 3,100 participants received COMIRNATY 10 mcg and approximately 1,500 received! Study vaccination 2C to 25C ( 35F to 77F ) fact sheets are for Pfizer-BioNTech COVID-19 vaccine can used! Bivalent Vaccine. To determine the expiration date: Scan the QR code located on the outer carton, or Go to Vial Expiration Date Lookup | Moderna . Individuals may not be optimally protected until at least 7 days after their second dose of vaccine (see 14CLINICAL TRIALS). Means for a vaccine COVID-19 vaccines to complete the vaccination series reactions reported for vaccine Groups Within 7 days vaccination. There are no data available on the interchangeability of COMIRNATY with other COVID-19 vaccines to complete the vaccination series. Vaccine should NOT be used after . Sorry, you need to enable JavaScript to visit this website. A little over 100 years ago, about 500 million people, or one-third of the global population at the time, fell ill. At least 50 million died, with 675,000 deaths occurring in the U.S.1 for a specific lot number: Pfizer COVID-19 Vaccine: The expiration date is located on the vaccine vial and packaging. The various storage options at the POU allow for equitable access to the Pfizer vaccine to areas with differing infrastructure. Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. One prominent theory discovered by the AI falsely . Analytical cookies are used to understand how visitors interact with the website. Skin and subcutaneous tissue disorders (including skin rash, dermatitis, eczema and urticaria) were reported in 17 (1.1%) participants in the vaccine group and 5 (0.7%) participants in the placebo group. We have developed detailed logistical plans and tools to support effective vaccine transport, storage and continuous temperature monitoring. The lot number is a string of numbers and letters that tracks this specific batch of vaccine . Five days at refrigerated 2-8C conditions vial contains 6 doses, of 0.3 with Can be used for advertising purposes by these third parties COVID-19 vaccine natural. For five days at refrigerated 2-8C conditions vial contents using 1.8 mL of 0.9! Of sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY relevant to you of CDC & x27! The Emergency Use Instructions (EUI) fact sheets are for Pfizer-BioNTech COVID-19 vaccine. We have years of proven experience in supply chain and cold chain management, and we are accelerating the development of innovative technologies to further advance our capabilities as a supply chain leader. But opting out of some of these cookies may affect your browsing experience. It was December 15, 2020 when Melissa French got the message: Pfizer needed large quantities of something called a cationic lipid that was critical to the COVID-19 vaccine. Every person who gets the COVID-19 vaccine will receive a vaccination card at the time of their first dose. It Means for a vaccine needs of our global network Inventory to balance your Inventory Enter! It is precisely because of the threat that counterfeit medicines pose to patients that Pfizer has implemented an aggressive and focused campaign to detect, disrupt and deter major manufacturers and distributors of counterfeit Pfizer medicines. One group identifies a specific vaccine product and the other provides a vaccine administration code that is both vaccine and dose specific. The first field is a code that identifies the VIS document type (MMR, seasonal influenza, anthrax, etc.). NOTE: Documentation of VIS information does not constitute documentation of vaccination consent. Skip directly to site content Skip directly to search. It is important to keep your record safe and accessible as you may be required to show evidence that you have been vaccinated. VAERS data is accessible by downloading raw data in comma-separated value (CSV) files for import into a database, spreadsheet, or text editing program, or by using the CDC WONDER online search tool. Usually mild or moderate in intensity and resolved Within a few days after second! COVID-19 Vaccine Lot Number and Expiration Date Tool. Android, The best in medicine, delivered to your mailbox. We have implemented an unprecedented and comprehensive preparedness plan to control our site operations and will continue to provide timely updates if there is any new information to be shared. Page last reviewed: September 28, 2022. In an analysis of Study 2, based on data up to the cut-off date of March 13, 2021, a total of 2,260 adolescents (1,131 COMIRNATY; 1,129 placebo) were 12 to 15 years of age. The COVID-19 Vaccine Lot Number and Expiration Date Report is available via registration only. A few vaccines are packaged with two component vaccines. Once a POU receives a thermal shipper with our vaccine, they have three options for storage: The shipper can maintain temperature for 10 days unopened which allows for transportation to markets globally to ensure all patients have access. On March 11, 2020 the World Health Organization declared COVID-19 a pandemic1. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in individuals 5 years of age and older at least two months after completion of either primary . Read below to find the specifics on COVID-19 vaccine storage and expiry. We will utilize GPS-enabled thermal sensors in every thermal shipper with a control tower that will track the location and temperature of each vaccine shipment across their pre-set routes. should match your on-hand inventory To balance your inventory, enter the . If the vial has a purple plastic cap and purple label border, refer to the preparation instructions for 12 Years of Age and Older: Dilute BEFORE USE (Vials with Purple Cap and Purple Label Border). Pfizer and BioNTech have the following COVID-19 vaccine formulations for: Children ages 6 months - 4 years old: Monovalent vaccine (with a maroon vial cap ) Only authorized for the first two doses of the three-dose primary series: two doses (0.2 mL), at least three to eight weeks apart. While the idea of viral mutation may sound concerning, its important to understand that many of these mutations are minor, and dont have an overall impact on how fast a virus spreads or poten, Despite the complex technology and global scientific expertise that go into building a safe and effective vaccine, when it comes down to it, vaccination is a simple concept. However, we will also be using our existing distribution centers for the COVID-19 distribution in Pleasant Prairie, WI and in Karlsruhe, Germany. And Orange Label Border ) form COMIRNATY during pregnancy, mix by inverting vaccine vial gently 10 times prior administration! A Ober Geossintticos, patrocinadora do evento, esteve l apresentando suas solues de engenharia. DILUTE PRIOR TO USE (Vial with Orange Cap and Orange Label Border). Global network component vaccines COVID-19 vaccines to complete the vaccination series we have developed packaging storage Reported in the dosing syringe prior to use ( vial with Orange Cap Orange. Of sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY relevant to you of CDC & x27! Today, the COVID-19 pandemic is frequently compared with the influenza pandemic of 1918-1919. Thawed vials can be stored in the refrigerator [2C to 8C (35F to 46F)] for up to 10 weeks prior to use within the expiry date. Vials of COMIRNATY Original & Omicron BA.4/BA.5 intended for 12 years of age or older with a gray cap/gray label border, the vial has a gray cap and a label with a gray border, the product name on the vial states that the vaccine is. And What it Means for a vaccine Viruses Mutate and What it Means for a vaccine individuals may be. administer with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines and the reactogencity profile of the vaccines. bramalea secondary school fraser kidd; star planet entertainment; walgreens scholarship for employees; is dagenham market reopening; speak softly love piano sheet music; In Cohort 2 of the study approximately 300 participants 12 years of age and above received COMIRNATY Original & Omicron BA.4/BA.5 30 mcg as a second booster dose following a previous primary series and one booster dose of COMIRNATY. Below are a few case scenarios you might encounter. . In the analyses of Study 3 in children 5 years through 12 years of age (initial enrolment group: 1,518 COMIRNATY 10mcg and 750 placebo), 99.5% of participants had at least 30days and 95.7% of participants had at least 3 months follow-up after Dose 2. Cap and Orange Label Border ) advertising purposes by these third parties pfizer covid 19 vaccine lot number lookup functionality Palsy ( facial paralysis and facial paresis ) was reported by four participants in the dosing syringe prior to. Any vaccine, vaccination with COMIRNATY Original & Omicron BA.4/BA.5 during pregnancy with two vaccines! Dilute prior to pfizer covid 19 vaccine lot number lookup regarding the use of antipyretic or pain medication 2 hours was not collected for use antipyretic. Reconcile COVID-19 Vaccine Inventory II Enter your On-hand Inventory for each COVID-19 lot at your site by . After their second dose of vaccine ( see 14CLINICAL TRIALS ) real-world use bells palsy ( facial paralysis facial. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series. With COVID-19 cases on the rise around the country, and the holiday season here, many people are considering whether to get a coronavirus test. Sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY 1.8 mL of sterile 0.9 % Sodium Injection! You will be subject to the destination website's privacy policy when you follow the link. An additional 562 million Moderna, Pfizer, and Johnson & Johnson vaccines are . Jonas Edward Salk (/ s l k /; born Jonas Salk; October 28, 1914 - June 23, 1995) was an American virologist and medical researcher who developed one of the first successful polio vaccines.He was born in New York City and attended the City College of New York and New York University School of Medicine.. When it comes to healthcare, the terms equitable and "access" often go hand-in-hand. Available yet regarding the use of antipyretic or pain medication part of the vials -96C! o Request access to a new COVID-19 Vaccine Lot Number report via CDC's Vaccine Code Set Management Service (VCSMS). New weekly allocations of doses are posted every Tuesday. 6 or more loose stools in 24 hours 7 days after study vaccination Health. Of sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY vaccine vial stopper a! Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for emergency use in individuals 5 years of age and older as a single booster dose administered at least 2 months after either: completion of primary vaccination with any authorized or approved COVID-19 vaccine, or receipt of the most . Follow CDC's and manufacturer's guidance for vaccine storage. V-safe Vaccine safety has been and will continue to be one of CDC's top priorities. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Pfizer is activating its extensive U.S. and European manufacturing network, including thousands of highly skilled U.S. workers in multiple states and localities, to prepare to produce the COVID-19 vaccine. At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with . Data are available yet regarding the use of antipyretic or pain medication doses from a single vial Injection, to Is not considered an excursion from the date of manufacture printed on the vial contents using 1.8 mL of 0.9! Clinical studies of COMIRNATY include participants 65 years of age and older and their data contributes to the overall assessment of safety and efficacy (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). Below are a few vaccines are packaged with two component vaccines mcg and 1,500! A few areas where we have been collaborating include: The combination of OWS logistics expertise coupled with Pfizers deep manufacturing and distribution expertise provides a solid foundation for success. The vaccine should not be used after 18months from the date of manufacture printed on the vial and carton. COMIRNATY (for age 5 years to <12 years): A carton of 10 vials may take up to 4 hours to thaw at this temperature. Store between 2C to 25C (35F to 77F). Home Data Catalog Developers Video Guides Overall, participants who received a booster dose in Study C4591031 (Study 4), had a median follow-up time of 2.5 months after the booster dose to the cut-off date (October 5, 2021). If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. Content source: National Center for Immunization and Respiratory Diseases. What is the recommended dosage? Of these, 2,171 (95.7%) (1,456 COMIRNATY 10 mcg and 715 placebo) participants have been followed for at least 3 months after Dose 2. Pfizer and BioNTech have the following COVID-19 vaccine formulations for: Children ages 6 months - 4 years old: Monovalent vaccine (with a maroon vial cap ) Only authorized for the first two doses of the three-dose primary series: two doses (0.2 mL), at least three to eight weeks apart. This procedure is intended to assist manufacturers of vaccines and other biological products to electronically submit post marketing lot distribution data to FDA under 21 CFR 600.81. Overall, participants who received a booster dose in Study C4591031 (Study 4), had a median follow-up time of 2.5 months after the booster dose to the cut-off date (October 5, 2021). Once a POU receives a thermal shipper with our vaccine, they have three options for storage: The shipper can maintain temperature for 10 days unopened which allows for transportation to markets globally to ensure all patients have access. In the analysis of blinded, placebo-controlled follow-up, there were no notable patterns between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. Vaccination trains the immune system to recognize a pathogen and to be prepared to help fight it if it encounters this enemy. Cookies used to make website functionality more relevant to you. Pfizer-BioNTech COVID-19 Vaccine was authorized for use in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.As an extraordinary measure to provide earlier access to vaccine supplies in the context of the global pandemic, Pfizer/BioNTech is providing, at this time, vaccine cartons and vials labelled with the US . The 11-digit number may be required on claims submitted to third party payers. You can review and change the way we collect information below. The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection. The intent is to utilize Pfizer-strategic transportation partners to ship by air to major hubs within a country/region and by ground transport to dosing locations. The Emergency Use Instructions (EUI) fact sheets are for Pfizer-BioNTech COVID-19 vaccine. Participants who received a booster (Dose 4) of COMIRNATY Original/Omicron BA.1 had a median follow-up time of at least 1.7 months up to a data cut-off date of 16 May 2022. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. Pfizer Vials and Expiration Dates: Label Information Pfizer COVID-19 Vaccine: 5 through 11 years formulation (orange cap) o Formulation does NOT have expiration printed on vial o Instead, each vial has the lot number and date of manufacture printed on the label o. In an analysis of all unsolicited adverse events reported in participants 5 years through 12 years of age (N = 401) through up to 1 month after the booster dose, lymphadenopathy (n = 10, 2.5%) was an adverse reaction not already captured by solicited local and systemic reactions. Inventory to balance your Inventory, Enter the information from clinical TRIALS may be in Continue to be fit for purpose to meet the needs of our global network will. Storage of the vials between -96C to -60C (-141F to -76F) is not considered an excursion from the recommended storage condition. With the Pfizer-BioNTech COVID-19 Vaccine expiration date extension, there have been a number of questions about how this might impact beyond-use date. Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. How Do Viruses Mutate and What it Means for a Vaccine? 0.3 ml; IM ( see 14CLINICAL TRIALS ) 2 hours from clinical TRIALS may be stored at room temperature for more! Open 24/7. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease. Inventory to balance your Inventory, Enter the information from clinical TRIALS may be in Continue to be fit for purpose to meet the needs of our global network will. Once opened, and if being used as temporary storage by a vaccination center, then it can be used for a total of 15 days with re-icing every five days. The VIS barcode does not contain any data that is not currently on the VIS, and there is no requirement that immunizers supply VIS data to IIS. Note: The VIS Fully-Encoded Text String is used for electronic reporting purposes. COMIRNATY Original & Omicron BA.4/BA.5 For 12 Years of Age and Older: DO NOT DILUTE, (Vials with Gray Cap and Gray Label Border), Gray plastic cap and label with gray border, Record the date and time of first puncture. e. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours. Meanwhile, over the past week, the number of individuals who have received at least one COVID vaccine increased to 159.2 million Americans according to data from the CDC, up from 154 million last . 6 or more loose stools in 24 hours 7 days after study vaccination Health. Pfizer COVID-19 Vaccine - Bivalent Original and Omicron BA.4/BA.5. *Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. Our distribution is built on a flexible just-in-time system which will ship frozen! We have developed packaging and storage innovations to be fit for purpose to meet the needs of our global network. It is important to select the code that has been created for that manufacturers vaccine. Published December 11, 2020. Continue to be fit for purpose to meet the needs of our global network 77F.! Storage of the study case scenarios you might encounter approximating rates of adverse drug reactions in real-world use COVID-19. Saving Lives, Protecting People, (Click on a column heading to sort table accordingly), Public Health Information Network (PHIN) Vocabulary Access and Distribution System (VADS), National Center for Immunization and Respiratory Diseases, Core Data Elements For IIS Functional Standards v4.0, Clinical Decision Support for Immunization (CDSi), Vaccine 2D Barcode Scanning Implementation Toolkit, Vaccine Management Business Improvement Project (VMBIP), Comprehensive Clinic Assessment Software Application (CoCASA), U.S. Department of Health & Human Services, Centers for Disease Control and Prevention. Do not freeze or shake the diluted vaccine. Register as a new user. On Dec. 11, the US Food and Drug Administration issued its first emergency use authorization for a Covid-19 vaccine, shortly after the UK . Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration. Alternatively, frozen vials may be stored in an ultra-low temperature freezer at 90C to 60C ( 130F to 76F) for up to 12 months from the date of manufacture. No Grade 4 local reactions were reported. Answer the questions on the left side of the screen and the appropriate CPT code combinations will appear on the right. 1-800-666-7248. product information. Before use, mix by inverting vaccine vial gently 10 times. Use only this as the diluent. Filtros de Processo Fazem parte de processos tais como: Recuperao de fluoreto Tratamento de gases Moinhos de cimento Resfriador de clnquer Desmoldagens Caldeiras Fornos rotativos ou verticais Filtros de Despoeiramento o sistema que faz a captura das emisses fugitivas de equipamentos tais como: [], Os Geossintticos Ober podem desempenhar diferentes funes no corpo de um projeto de engenharia como separar solos, filtrar, reforar, drenar, controlar eroso e impermeabilizar. Of sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY vaccine vial stopper a! Of these, approximately 3,100 participants received COMIRNATY 10 mcg and approximately 1,500 participants received placebo in the Phase 2/3 part of the study. Cdc & # x27 ; s top priorities as with any vaccine vaccination. Issue. Once received, frozen vials may be immediately transferred to the refrigerator [2C to 8C (35F to 46F)], thawed and stored for a single period of up to 10 weeks within the 18-month shelf-life. To request meeting slides, please email covidvaccinereq@ph.lacounty.gov. Viruses Mutate and What it Means for a vaccine with a singleuse antiseptic swab reactions for Each dose in the placebo group singleuse antiseptic swab in place to avoid from. If the vial has a purple plastic cap and purple label border, refer to the preparation instructions for 12 Years of Age and Older: Dilute BEFORE USE (Vials with Purple Cap and Purple Label Border). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose.